{
    "clinical_study": {
        "@rank": "38614", 
        "arm_group": {
            "arm_group_label": "Idarubicin + Cytarabine + DLI", 
            "arm_group_type": "Experimental", 
            "description": "Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)"
        }, 
        "brief_summary": {
            "textblock": "The primary hypothesis is that chemotherapy followed by donor lymphocyte infusion (DLI) from\n      HLA-haploidentical donors is a safe procedure that will not cause Graft versus Host Disease\n      (GVHD) or increased treatment-related mortality. The Investigator further believes that this\n      will improve outcomes of elderly patients with high-risk AML or MDS compared to chemotherapy\n      alone, and that that this benefit will be even greater in donor-recipient pairs that share\n      maternal-fetal microchimerism or non-inherited maternal antigen (NIMA) mismatch.  A large\n      part of this trial will include immune function assays as well as assessments of efficacy,\n      toxicity, and GVHD. Because this therapy may be a tolerable alternative to allogeneic\n      hematopoietic stem cell transplantation (alloHSCT) for elderly patients, the Investigator\n      will validate functional measurements (e.g. Comprehensive Geriatric Assessment (CGA)) with\n      biologic correlates (cytokine and genomic profiles) and clinical outcomes."
        }, 
        "brief_title": "Adoptive Transfer of Haplo-identical DLI for AML and MDS", 
        "completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Myelodysplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects must have their diagnosis of high-risk AML or high-risk MDS confirmed by\n             pathologic review of bone marrow biopsy according to WHO guidelines\n\n          2. Patients will be defined as high risk AML and thus eligible if they meet one or more\n             of the following criteria:\n\n               1. Secondary AML (from underlying MDS or therapy related)\n\n               2. Presence of complex cytogenetic abnormalities (3 or more cytogenetic\n                  abnormalities), all monosomies, del 5q, del 7q, inv3, t(3;3), t(6;9), t(9;22),\n                  abn 11q23 (excluding t(9;11))\n\n               3. Fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutation\n                  positive\n\n          3. Patients will be defined as high risk MDS and thus eligible if they have a MD\n             Anderson Comprehensive Cancer MDS Risk  Score \u22659\n\n          4. Subjects must have Eastern Cooperative Oncology Group (ECOG) Performance status of\n             0,1,or 2; if ECOG 2, they must also have a Charlson comorbidity index of \u22645.\n\n          5. Subjects must be 55 years of age or older\n\n          6. Subjects should have a 3-5/6 HLA-matched related haploidentical donor who is\n             evaluated and deemed able to provide DLI.\n\n          7. Patient should be able to provide informed consent\n\n          8. Subjects must have a multigated acquisition (MUGA) and /or ECHO or cardiac magnetic\n             resonance imaging (MRI).  The required minimum standards include MUGA or ECHO or\n             cardiac MR showing an ejection fraction( EF) of 40%.  Those with an EF 40-49% must\n             also have a cardiologist consult and assist with management.\n\n          9. Pulmonary function tests (PFTs) with diffusing capacity of lung for carbon monoxide\n             (DLCO) are conditional for subjects at the discretion of the physician.  The required\n             minimum standards for those who have PFTs include DLCO of 40%.  Those with DLCO of\n             40-49% must have a pulmonologist consult and assist with management.\n\n         10. Subjects of all genders and races are eligible\n\n        Exclusion Criteria:\n\n          1. Pregnant or lactating women.\n\n          2. Patients with other major medical or psychiatric illnesses which the treating\n             physician feels could seriously compromise tolerance to this protocol\n\n          3. Patients with known active central nervous system (CNS) disease\n\n          4. Patients with acute promyelocytic leukemia (FAB M3)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046122", 
            "org_study_id": "Pro00043247"
        }, 
        "intervention": [
            {
                "arm_group_label": "Idarubicin + Cytarabine + DLI", 
                "description": "Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.\nSubjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy.", 
                "intervention_name": "Idarubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Idarubicin + Cytarabine + DLI", 
                "description": "Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.\nSubjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation.", 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Idarubicin + Cytarabine + DLI", 
                "description": "HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.\nSubjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation.", 
                "intervention_name": "DLI", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Idarubicin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Efficacy of Chemotherapy Combined With Adoptive Transfer of Human Leukocyte Antigen (HLA)-Haploidentical Donor Lymphocyte Infusion (DLI) in Older Patients With Righ-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)", 
        "overall_contact": {
            "email": "julie.warzecho@dm.duke.edu", 
            "last_name": "Julie Warzecho, RN, OCN", 
            "phone": "919-681-4769"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Arati Rao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Unacceptable toxicity is defined as:\ni. Grade III or IV acute GVHD (aGVHD) of the gut or liver or Grade IV aGVHD of the skin lasting > 7 days;\nii. Grade IV Common Terminology Criteria for Adverse Events (CTCAE) toxicity attributable to DLI (e.g. infusion reaction, as opposed to Grade IV CTCAE toxicity from chemotherapy) and lasting >7 days\niii. Treatment-related mortality (TRM)", 
            "measure": "Number of subjects with unacceptable toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "up to 8 weeks after last cell infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046122"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "1 year disease free survival rate following adoptive transfer", 
                "measure": "Disease free survival", 
                "safety_issue": "No", 
                "time_frame": "one year following adoptive transfer"
            }, 
            {
                "description": "Overall survival 2 years after completing adoptive transfer therapy", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years after completing therapy"
            }, 
            {
                "description": "Grade III or IV aGVHD of the gut or liver or Grade IV aGVHD of the skin lasting > 7 days", 
                "measure": "Rate of acute GVHD", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks after last cell infusion"
            }, 
            {
                "description": "Grade IV CTCAE toxicity attributable to DLI (e.g. infusion reaction, as opposed to Grade IV CTCAE toxicity from chemotherapy) and lasting >7 days, Grade III or IV aGVHD of the gut or liver or Grade IV aGVHD of the skin lasting > 7 days, or death", 
                "measure": "Rate of unacceptable toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks after the last cell infusion"
            }, 
            {
                "description": "Efficacy as measured by the percentage of subjects with a complete remission.", 
                "measure": "Rate of Efficacy", 
                "safety_issue": "No", 
                "time_frame": "2 years after completing therapy"
            }, 
            {
                "description": "Immune recovery determined by measurements of cytokine profiles, lymphocyte and natural killer (NK) enumeration and flow-based assays, measured prior to induction, prior to each round of consolidation, 8 weeks after the last cycle of consolidation, and every 3 months after treatment for up to 2 years", 
                "measure": "Rate of Immune Recovery", 
                "safety_issue": "No", 
                "time_frame": "2 years after completing therapy"
            }, 
            {
                "description": "Hematopoietic recovery as measured by  the date of the first of three consecutive laboratory values where the absolute neutrophil count (ANC) \u2265 500/\u03bcl , the date of the first of three consecutive laboratory values obtained on different days where the platelet count was > 20,000/\u03bcl without transfusion.", 
                "measure": "Rate of Hematopoietic recovery", 
                "safety_issue": "No", 
                "time_frame": "2 years after completion of therapy"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}